An observational study in Lymphedema and Lipedema, sponsored by Kayseri City Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Kayseri City Hospital · Observational
The aim of this observational study is to evaluate the diagnostic value of multimodal ultrasonography in differentiating between lymphedema and lipedema. Differentiating these two chronic conditions based solely on clinical examination can be challenging due to overlapping symptoms. This study will utilize various non-invasive ultrasound techniques-including B-mode ultrasound, strain elastography, power Doppler, and quantitative ImageJ analysis-to compare tissue characteristics among patients with lymphedema, patients with lipedema, and healthy controls. The goal is to identify reliable, non-invasive imaging biomarkers that can facilitate early and accurate diagnosis, thereby optimizing patient management.
Lymphedema and lipedema are distinct pathological entities that often present with similar clinical features, particularly in the lower extremities. Accurate differential diagnosis is crucial for appropriate therapeutic intervention. While modalities like lymphoscintigraphy serve as standard diagnostic tools for lymphedema, they are invasive and not universally accessible. High-resolution ultrasonography provides a practical, non-invasive alternative for tissue assessment.
This cross-sectional, observational study will recruit participants and categorize them into three groups: a lymphedema group, a lipedema group, and a healthy control group. Comprehensive multimodal ultrasound evaluations will be performed on all participants. The assessment protocol includes:
B-mode Ultrasonography: To measure the thickness of the dermis and subcutaneous tissue layers.
Strain Elastography: To evaluate the biomechanical properties and relative stiffness of the affected tissues.
Power Doppler: To assess the local microvascularity and blood flow patterns.
ImageJ Software Analysis: To perform quantitative pixel-based echogenicity evaluation of the ultrasound images.
By systematically comparing these ultrasonographic parameters across the three groups, this study aims to establish standard, reproducible imaging criteria. The primary objective is to determine which specific ultrasound modalities, or combinations thereof, offer the highest diagnostic accuracy in differentiating lymphedema from lipedema in clinical practice.
529 studies on the registry are indexed under Lymphedema; 131 are open to participants now.
This study's enrollment of 75 is below the median of 103 across 145 observational studies indexed under Lymphedema.
Browse Lymphedema studies →Kayseri City Hospital is the lead sponsor of 49 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 3, 2026. See what changed
The study population consists of patients presenting to the Physical Medicine and Rehabilitation outpatient clinic with complaints of lower extremity swelling, diagnosed clinically with either lymphedema or lipedema. A healthy control group, matched for general demographic characteristics, will be recruited from volunteers without any lower extremity pathologies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals aged 18 to 65 years.
Clinical diagnosis of lower extremity lymphedema (for the lymphedema group).
Clinical diagnosis of lower extremity lipedema (for the lipedema group).
Healthy individuals with no history or clinical signs of chronic lower extremity edema (for the control group).
Exclusion Criteria:
Presence of active local infections, such as cellulitis or erysipelas, in the lower extremities.
History of deep vein thrombosis (DVT) or severe chronic venous insufficiency.
Systemic conditions that can cause secondary edema, including congestive heart failure, chronic kidney disease, or severe hepatic impairment.
Previous surgical interventions on the affected lower extremities, including liposuction, lymphatic reconstructive surgery, or major orthopedic surgeries.
Active or currently undergoing radiotherapy/chemotherapy.
Pregnancy or lactation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients clinically diagnosed with lower extremity lymphedema. Participants in this group will undergo a non-invasive multimodal ultrasound assessment (including B-mode, strain elastography, power Doppler, and ImageJ analysis) to evaluate tissue characteristics.
Diagnostic Test: Multimodal Ultrasound Assessment
Patients clinically diagnosed with lipedema of the lower extremities. Participants in this group will undergo the identical non-invasive multimodal ultrasound assessment protocol to evaluate tissue echogenicity, thickness, and stiffness.
Diagnostic Test: Multimodal Ultrasound Assessment
Healthy volunteers with no history or clinical signs of chronic lower extremity edema, lymphedema, or lipedema. This group will undergo the same multimodal ultrasound assessment to establish baseline normative values for comparison.
Diagnostic Test: Multimodal Ultrasound Assessment
A comprehensive, non-invasive ultrasonographic evaluation of the lower extremities. The protocol includes B-mode ultrasound for measuring dermis and subcutaneous tissue thickness, strain elastography for assessing tissue biomechanical stiffness, and Power Doppler for evaluating local microvascularity. Additionally, quantitative echogenicity of the tissues will be analyzed using ImageJ software.
Also known as: B-mode Ultrasonography, Strain Elastography, Power Doppler, ImageJ Analysis
Dermal and Subcutaneous Tissue Thickness
Measurement of the dermal and subcutaneous tissue layers in millimeters (mm) using high-resolution B-mode ultrasonography to identify anatomical differences between the groups.
Time frame: Day 1 (At the time of ultrasound assessment)
Tissue Stiffness Assessment via Strain Elastography
Evaluation of the biomechanical properties and relative stiffness of the subcutaneous tissue, assessed through color-coded elastogram scoring maps.
Time frame: Day 1 (At the time of ultrasound assessment)
Quantitative Echogenicity Analysis
Pixel-based quantitative evaluation of tissue echogenicity from ultrasound images, analyzed using ImageJ software to establish objective imaging biomarkers.
Time frame: Day 1 (At the time of ultrasound assessment)
Visual Analogue Scale (VAS) for Pain
Assessment of the intensity of lower extremity pain reported by the participants on a scale from 0 (no pain) to 10 (worst imaginable pain).
Time frame: Day 1 (Baseline clinical evaluation)
Plan to share: No — Individual participant data (IPD) will not be shared publicly to maintain participant confidentiality and in accordance with the policies of the institutional ethics committee. However, the study protocol and statistical analysis plan may be available upon reasonable request to the principal investigator.
Ran from Sep 2025 to primary completion in Feb 2026, 5 months.
Of 56 non-industry observational studies under Lymphedema, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 108. This study's 5 months is below that.
Counting every sponsor, half of 59 studies reached it within 45 months; a quarter within 12 and three quarters within 108.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start Mar 2026 → Sep 2025, primary completion Aug 2026 → Feb 2026 and completion Sep 2026 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kayseri City Hospital